WebMD Global requires every individual in a position to control educational content to disclose all financial relationships
with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary
business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed
below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Disclosures for additional planners can be found here.
Faculty

-
Karine Lacombe, MD, PhD
Professor of Infectious Diseases
Sorbonne University
Head, Infectious and Tropical Diseases Department
Saint-Antoine Hospital
Inserm, Institut Pierre Louis de Santé Publique
Paris, France
Disclosures
Karine Lacombe, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: Diaccurate; Gilead Sciences; Janssen; Merck Sharp & Dohme; Moderna; SpikImm; ViiV Healthcare
Research funding from: Merck Sharp & Dohme
Owns bonds from: SpikImm

-
Saul N. Faust, MBBS, PhD, FRCPCH
Professor, Paediatric Immunology
and Infectious Diseases
Director
NIHR Southampton Clinical Research Facility
University Hospital Southampton NHS Foundation Trust
University of Southampton
Southampton, United Kingdom
Disclosures
Saul N. Faust, MBBS, PhD, FRCPCH, has the following relevant financial relationships:
Consultant or advisor for: Johnson & Johnson; Pfizer, Inc.; Sanofi; Seqirus (former)
Speaker or member of speakers bureau for: Moderna; Novavax
Research funding from: AstraZeneca; GlaxoSmithKline; Johnson & Johnson; Merck; Pfizer, Inc.; Sanofi; Valneva
Editor
Compliance Reviewer
Peer Reviewer
This activity has been peer reviewed and the reviewer has no relevant financial relationships.